NEWS
Novo Nordisk Faces Setback as Obesity Drug Trial Falls Short

Novo Nordisk has faced a major setback after releasing disappointing trial data for its latest obesity drug, CagriSema. The announcement caused a sharp drop in the company’s stock, with its American depositary receipts falling by as much as 28% at one point and eventually stabilizing at an 18% decline, trading at $83.87 in premarket trading. In Denmark, the company’s Copenhagen-listed shares dropped 23% by midday trading, marking a significant decline for the pharmaceutical giant renowned for its blockbuster drugs Ozempic and Wegovy.
The clinical trial for CagriSema revealed that patients who used the drug experienced an average weight loss of 22.7% over 68 weeks. While this result outperformed Novo’s older treatments, it fell short of the company’s ambitious 25% weight-loss target. Further, only 40% of trial participants achieved a weight loss of 25% or more, a figure that disappointed both investors and analysts.
CagriSema is a combination drug that merges semaglutide, the active ingredient in Ozempic and Wegovy, with cagrilintide, another promising component. Despite its improved performance compared to Novo’s existing treatments, CagriSema barely edged out Eli Lilly’s competing drug, Mounjaro, which demonstrated a weight reduction of 22.5% in trials. This slight difference failed to inspire confidence in Novo’s ability to deliver a market-leading product.

Novo Nordisk Stock Drops After Obesity Drug Trial Miss
In contrast, shares in Eli Lilly, Novo’s primary competitor, surged following the announcement. Eli Lilly’s stock rose 9% to $825.37, reflecting investor optimism about the company’s position in the obesity treatment market. Lilly, which also produces Mounjaro and Zepbound, is now seen as a stronger competitor as it continues to challenge Novo for dominance in the lucrative market for obesity and Type 2 diabetes drugs.
Novo Nordisk and Eli Lilly have long been at the forefront of this market, but competition is increasing as other pharmaceutical companies work to develop their own treatments. Obesity and diabetes drugs have become a critical focus within the pharmaceutical industry due to rising obesity rates worldwide and the growing demand for effective solutions. Analysts have predicted that the market for weight-loss drugs could grow to $200 billion by the early 2030s. However, recent events have cast doubt on the extent of demand for these treatments, leading to heightened scrutiny from investors.
The disappointing trial results for CagriSema have raised questions about Novo Nordisk’s ability to maintain its leadership in the obesity drug market. The company has enjoyed tremendous success with Ozempic and Wegovy, which have gained widespread recognition for their effectiveness. However, the high expectations surrounding CagriSema underscore the intense competition and the challenges of meeting both medical and market demands.
Eli Lilly’s strong market performance highlights the shifting dynamics in the weight-loss drug sector. With its effective treatments and competitive pricing, Lilly has successfully expanded its footprint, attracting both patients and investors. The company’s stock surge following Novo’s announcement underscores its ability to capitalize on rival missteps and strengthen its position as a leading player.
Despite the challenges faced by Novo Nordisk, the potential for growth in the weight-loss drug market remains significant. Rising obesity rates and advancements in pharmaceutical science have created a substantial demand for effective treatments. However, the market is becoming increasingly crowded as more companies enter the space, intensifying competition and raising the stakes for innovation.
Novo’s setback with CagriSema also reflects broader concerns about affordability and accessibility in the weight-loss drug market. While these treatments have demonstrated significant potential, their high cost has raised questions about their accessibility to a broader population. Addressing these concerns will be crucial for companies aiming to sustain growth in this sector.

Novo Nordisk Stock Drops After Obesity Drug Trial Miss
The future of obesity and diabetes treatments will likely hinge on the ability of companies like Novo Nordisk and Eli Lilly to navigate these challenges and continue to innovate. The clinical trial results for CagriSema serve as a reminder of the complexities involved in developing breakthrough drugs that meet both clinical and market expectations.
For Novo Nordisk, the focus will now shift to rebuilding investor confidence and addressing the shortcomings highlighted by the trial data. The company has a strong history of success in the obesity and diabetes markets, but it will need to demonstrate its ability to adapt and innovate in the face of growing competition.
Eli Lilly, on the other hand, is well-positioned to capitalize on its recent success. The company’s diverse product portfolio and strategic moves to expand its market presence have strengthened its competitive advantage. Lilly’s ability to maintain momentum and continue delivering strong results will be critical to its long-term success.
As the market for obesity drugs continues to evolve, the race to innovate will intensify. Both Novo Nordisk and Eli Lilly will need to address key challenges, such as improving affordability, demonstrating long-term efficacy, and navigating the complexities of regulatory approval. The stakes are high, but the potential rewards are even higher, as the demand for effective weight-loss treatments continues to grow.
Novo Nordisk’s disappointing trial results have undoubtedly dealt a blow to the company’s stock and market reputation. However, the broader outlook for the weight-loss drug market remains optimistic. With continued advancements in pharmaceutical science and a growing focus on addressing global health challenges, the future of obesity and diabetes treatments holds promise, even amid the current setbacks. The coming months will be critical for Novo Nordisk as it works to recover from this setback and reaffirm its position as a leader in the pharmaceutical industry.
NEWS
Shannon Sharpe’s Wild Sky Bri Comment Goes Viral Amid $50M Assault Lawsuit: “She Played On Her Back!

Shannon Sharpe is under fire in 2025, and it has nothing to do with his NFL career or infectious sportscasting personality. Two unconnected controversies have combined to catapult him into the public eye in a manner few ever would have imagined. On one front he has gone viral for saying something brash and provocative about the adult content creator Sky Bri on his podcast. On the other, he’s contending with a $50 million civil lawsuit over serious allegations of sexual misconduct. All this has made for headlines, online arguments and reputational hit jobs galore.
The first incident occurred during a recent episode of Nightcap, Sharpe’s podcast that he co-hosts with former NFL star Chad “Ochocinco” Johnson. When chatting about OnlyFans personality Sky Bri, Sharpe said something that took off and went viral. “She played on her back!” he said of her adult film work. The clip went viral on Twitter, TikTok and Instagram, where it was viewed millions of times. The internet responded with a combination of surprise, humor and anger. Some called Sharpe out for being disrespectful to sex workers and to those with such illnesses, while others pointed to the comment as part of Sharpe’s unfiltered act.
The backlash then led to a surge of response from pop culture commentators and influencers. There was widespread skepticism that Sharpe’s developing online personality had ventured too far from the credibility he accrued as a sports commentator. Famed for his pithy punditry and larger-than-life charisma, Sharpe is now being seen by some as edging ever closer to the territory of internet shock jock in saleable search for clicks. Commentators like DJ Akademiks and Kevin “No Chill” Morris, a YouTube critic, have suggested that Sharpe is stuck between the reality that made him and the circus of new media.
While social media users were busy debating the Sky Bri moment, a much more serious issue emerged. “Jane Doe,” a woman claiming to reside in California, sued Sharpe for sexual assault, battery, false imprisonment, and emotional distress. The lawsuit, which was submitted by high-profile attorney Tony Buzbee – who also represented clients in several high-profile sexual misconduct cases, demands more than 50 million dollars in compensation. Through his lawyer Lanny Davis, Sharpe unequivocally denied the claims, arguing that everything that transpired was consensual, and the meeting involved complicated role-play.
However, in a surprising turn of events, it was revealed that two weeks before filing the lawsuit, Jane Doe was offered a 10 million settlement, which she turned down: Sharpe plans to also file a lawsuit for defamation, arguing that this exchange was orchestrated to undermine his credibility. Upon filing the lawsuit, the plaintiff’s legal team released audio material, where Sharpe is heard yelling aggressively and threateningly. Davis claims that this material is removed from context and was recorded during an eventful role-play without consent.
“Labeling it assault is inaccurate, unethical, and perverse,” the lawyer said. This scandal is far from the first one involving Sharpe’s personal affairs. In the second half of 2024, a pornographic live video appeared on his personal Instagram account by accident. The clip with an explicit audio of Sharpe having intimate relations was viewed by tens of thousands of people before being removed. At that time, Sharpe claimed that his account was hacked. However, he later confessed on his podcast that it was him accidentally pressing the live button.
The series of controversies has raised concern at ESPN, where Sharpe currently serves as co-host of First Take. Formal action has not yet been taken, but insiders believe network executives are closely watching the situation. Sharpe, with his high-profile platform and millions of viewers, finds his behavior under the microscope in a way it never has been.
As these events unfold, the public gets to see how Sharpe not only is traveling through a period that could redefine his post-football legacy, but also begins to come to full understanding of Grantham and the life he helped save. Will his unvarnished, sometimes incendiary, delivery continue to resonate with audiences or will the crushing reality of legal woes and blowback shift the course of his media career? Whether this is a storm that passes over or the beginning of a longer unraveling, one thing is for sure: Shannon Sharpe is one of the most divisive sports and entertainment characters of Twentieth Year of The Millennium.
NEWS
Butler, Curry lead Warriors past Grizzlies, into playoffs

Jimmy Butler III and Stephen Curry responded by trying to shoot the Golden State Warriors into the playoffs, and they succeeded on Tuesday night, beating the Memphis Grizzlies, 121-116, and earning the seventh seed in the long and winding Western Conference postseason bracketing. The victory, part of the N.B.A. play-in tournament, means the Warriors will face the Houston Rockets in a best-of-seven first-round series beginning Sunday.
Butler had a monster game with 38 points, seven rebounds and six assists. A player with a reputation for clutch performances in high stakes games, “Playoff Jimmy” lived up to his moniker, making impactful plays at both ends of the floor. His energy helped relieve some pressure on Curry, who also had a huge night, scoring 37 points. Curry hit crucial shots late, including a baseline three-pointer with under two minutes to play, and another from the left wing with one minute remaining. He then added two important free throws with 5.4 seconds remaining to seal the victory.
The Grizzlies had one last opportunity to tie the game, but Santi Aldama failed to get the ball inbounds in time, resulting in a five-second violation that ended Memphis’s chances. Desmond Bane scored 30 points for Memphis, while Ja Morant added 22. The Grizzlies advance to face the winner of the Mavericks-Kings matchup for the final West playoff spot.
But the Golden State victory was not buoyed merely by star power, but solid team play. Butler turned in one of his best games since joining the Warriors at the trade deadline, making 12 of 20 shots and 12 of 18 free throws. It was his second straight game with 30 or more points and his highest output with the team. His aggressive play, particularly in important stretches, kept the Warriors in control even as Memphis mounted multiple runs.
Butler brought it back Golden State’s way with a steal and a dunk as Memphis started to hit its stride in the third quarter. Morant gave the Grizzlies a scare when he rolled his right ankle after stepping on Buddy Hield’s foot. In spite of the injury, he converted a three-point play that cut Memphis to within one point for a spell. Jaren Jackson Jr. had 18 points, while Zach Edey had 14 points and 17 rebounds. Edey hit two clutch free throws with 14.3 seconds left, but that wasn’t enough to change the course of the game.
Curry had it worse than his 52-point explosion against the Grizzlies’ defense earlier in the month. He went 9-for-22 from the field while enduring ongoing defensive pressure, especially from Scotty Pippen Jr., who fouled out. Curry never lost his nerve and he also never wavered in the game fixture when it still counted. He also collected eight rebounds and added four assists.
The game included numerous strong opening quarter by the Warriors highlighted by a run aided and abetted by Butler. He participated in four consecutive scoring plays, beginning with an assist to Gary Payton II for a backdoor dunk, followed by an alley-oop to Quinten Post for a three, and then a three-point basket and a traditional three-point play. Butler did not appear to be dealing with pain from the quadriceps injury he suffered in the Warriors’ previous game against the Clippers.
This victory meant that Golden State, a team that previously had never won a series in the play-in tournament before Tuesday, would take on the Memphis Grizzlies in an elimination game for the eighth and final playoff spot. Their seasons came to an end in both 2021 and 2024 during play-in games, including a gut-wrenching overtime defeat by Memphis at Chase Center in 2021. That history provided extra motivation for some veterans like Curry and Draymond Green, who were eager to not experience an early exit again.
The Warriors had wanted to avoid the play-in tournament entirely but that idea went out the window when they dropped their last regular-season game in overtime to the Clippers. That loss was their third at home in the final week of the season, and it also left their playoff path uncertain. But with this victory, they’ve secured their spot and now turn their attention to the coming series against Houston.
Golden State’s play indicates they are peaking at the right time. With Butler playing as well as he is next to Curry, they have a real dynamic duo to ride into the playoffs. Their resilience, chemistry and collective playoff experience could make them a dangerous foe for any team in the West.
NEWS
When are taxes due? Here’s the last day to file, how to file an extension before Tuesday

And if you haven’t filed your taxes for 2025 yet, you’re cutting it close. Tax Day is fast approaching, and if you don’t know the status of your refund — or if you’ll get one — now’s the time to find out. With the deadline approaching, there’s a lot to know about the key dates, how to ask for extra time if you need it and how long you could wait for a refund, according to the Internal Revenue Service, which anticipates that nearly 140 million Americans will file taxes in 2023.
Your taxes are due on Tuesday, April 15, 2025. When April 15 falls on a weekend or legal holiday, the deadline carries over to the following business day.” The deadline is extended to June 16, 2025, for Americans overseas. The timing matters, whether you’re filing electronically or mailing your return. For electronic submissions, your time zone and the date and time of your submission are what the IRS relies on to decide whether your return was timely filed. If you’re mailing a paper return, it must be properly addressed, postage must be paid, and the return must be postmarked on or before the due date.
If you are not quite ready to file by the deadline, the IRS has several options for requesting an extension. One is to file online for an automatic extension, using IRS Free File, which is open to everyone, no matter their income. Then there’s the traditional method of sending in Form 4868 — the Application for Automatic Extension of Time to File. You can also submit it via IRS e-filing partners or with assistance from a tax pro. When completing this form, estimate what you owe in taxes and then subtract any payments you made over the course of the year. Third, you can pay your estimated tax due online using one of the IRS payment options and check the box you are filing for an extension. This approach means you don’t have to file a separate extension form — and you’ll receive a confirmation number showing that the extension was granted.
There’s some good news for those living outside the United States: if you are a U.S. citizen or resident alien living abroad as of the original tax filing deadline, you’re entitled to an automatic two-month extension without filing anything.
Once you file your taxes, you’ll likely be wondering when your refund will arrive. The “ Where’s My Refund? tool. To access it, you’ll need your Social Security number or individual taxpayer ID number, your filing status and the exact refund amount on your return. Once you enter the information, the system will tell you if it received your return, if your refund has been approved or if it has been sent. When your refund is issued, it can take up to five days to appear in your bank account, or several weeks if you’re waiting for a check in the mail.
For the most part, the IRS issues refunds in a reasonably timely manner — most of them in less than three weeks if you filed electronically. But they warn taxpayers not to count on receiving their refunds by any date, particular if the funds are intended for either a large purchase or an important payment to make. If additional review is required, some returns may take longer to process.
There are a number of reasons your refund might be delayed. The IRS says common reasons for such letters include an error or missing information on the return, complications arising from identity theft or fraud, or certain adjustments to the child tax credit or the recovery rebate credit. Delays may also affect taxpayers who file for the earned income tax credit or the additional child tax credit in some cases. If you filed Form 8379 — called the Injured Spouse Allocation — the review process will likely take longer, too. And even once the IRS sends your refund, it can take a few extra days depending on how your bank or credit union processes everything.
Filing your taxes doesn’t need to be stressful, but with the deadline looming, you should definitely not wait until the last minute. Whether you need more time or only you’re just waiting for your refund, figuring out how the process works and acting correctly now can help prevent you from pulling your hair out later.
-
Celebrity11 months ago
Relationship Lessons from Jennifer Lopez and Ben Affleck
-
Entertainment1 year ago
Zendaya Opens Up About Racy Scenes and Family Reactions in New Film
-
Health Care1 year ago
Pink Eye(Conjunctivitis): What Is Commonly MISDIAGNOSED As PINK EYE?
-
Entertainment1 year ago
Zendaya and Tom Holland kiss at The London Challengers premiere.
-
Health Care1 year ago
WHO Scientist Urges Monitoring & Prep For Highly Pathogenic Bird Flu
-
NEWS1 year ago
Is Trump Going To Jail? Your Questions About Trump’s Trial Answered
-
Entertainment1 year ago
Chris Martin and Dakota Johnson reportedly got engaged years ago
-
Blog1 year ago
Google’s Layoffs Amid Record Profits: A Glimpse into AI’s Impact on the Workforce